Refractory/Relapsed Indolent Non-Hodgkin Lymphoma
1 clinical trials · Condition
◉ Watch Refractory/Relapsed Indolent Non-Hodgkin Lymphoma
| Record | Firm | Date |
|---|---|---|
| Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma (NCT01429025) | Alliance for Clinical Trials in Oncology | 2012-05-01 |
Track Refractory/Relapsed Indolent Non-Hodgkin Lymphoma automatically
Every clearance here is in the API, with alerts when new ones post.